Lyell Immunopharma Files 8-K Amendment

TL;DR

Lyell Immunopharma filed an 8-K amendment on Jan 10, 2025, updating financials as of Oct 31, 2024. No major news.

AI Summary

Lyell Immunopharma, Inc. filed an amendment (No. 1) to its Form 8-K on January 10, 2025, reporting events as of October 31, 2024. The filing primarily concerns financial statements and exhibits, with no specific new financial figures or material events detailed in the provided text.

Why It Matters

This amendment updates the company's filings with the SEC, indicating a procedural update rather than a new material event. Investors should review the full amendment for any specific changes.

Risk Assessment

Risk Level: low — The filing is an amendment to a previous report and does not introduce new material information or significant financial changes.

Key Players & Entities

• Lyell Immunopharma, Inc. (company) — Registrant
• October 31, 2024 (date) — Date of earliest event reported
• January 10, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share LYEL NASDAQ Global

Filing Documents

• lyel-20241031.htm (8-K/A) — 39KB
• ex-231.htm (EX-23.1) — 3KB
• ex-991.htm (EX-99.1) — 440KB
• ex-992.htm (EX-99.2) — 420KB
• ex-993.htm (EX-99.3) — 258KB
• 0001628280-25-001065.txt ( ) — 1391KB
• lyel-20241031.xsd (EX-101.SCH) — 2KB
• lyel-20241031_lab.xml (EX-101.LAB) — 21KB
• lyel-20241031_pre.xml (EX-101.PRE) — 12KB
• lyel-20241031_htm.xml (XML) — 3KB

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of Business Acquired The audited financial statements of ImmPACT as of and for the fiscal year ended December 31, 2023, including the related notes thereto, are filed herewith as Exhibit 99.1 to this Amendment and are incorporated herein by reference. The consent of Deloitte & Touche LLP, the independent registered public accounting firm of ImmPACT, is filed herewith as Exhibit 23.1 to this Amendment. The unaudited financial statements of ImmPACT as of and for the nine months ended September 30, 2024, including the related notes thereto, are filed herewith as Exhibit 99.2 to this Amendment and are incorporated herein by reference. (b) Pro Forma Financial Information The unaudited pro forma condensed combined balance sheet of the Company as of September 30, 2024, and the unaudited pro forma condensed combined statements of operations of the Company for the nine months ended September 30, 2024 and the fiscal year ended December 31, 2023, including the related notes thereto, giving effect to the Acquisition are filed herewith as Exhibit 99.3 to this Amendment and are incorporated herein by reference. The unaudited pro forma financial information gives effect to the Acquisition on the basis of, and subject to, the assumptions set forth therein in accordance with Article 11 of Regulation S-X. The unaudited pro forma condensed combined financial information included in this Amendment are presented for illustrative purposes only, contain a variety of adjustments, assumptions and estimates, and are not necessarily indicative of what the combined company's actual financial position or results of operations would have been had the Acquisition been completed during the periods presented therein. The combined company's actual results and financial position may differ materially from the unaudited pro forma condensed combined financial information included in this Amendment. (d) Exhibits Exhibit Numb

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lyell Immunopharma, Inc. Date: January 10, 2025 By: /s/ MATTHEW LANG Matthew Lang Chief Business Officer

View Full Filing

View this 8-K/A filing on SEC EDGAR